Prospera Financial Services Inc Has $2.38 Million Holdings in Zoetis Inc. $ZTS

Prospera Financial Services Inc decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 20.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,260 shares of the company’s stock after selling 4,053 shares during the quarter. Prospera Financial Services Inc’s holdings in Zoetis were worth $2,380,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC increased its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. NewSquare Capital LLC grew its stake in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of Zoetis during the third quarter worth $39,000. SJS Investment Consulting Inc. increased its holdings in shares of Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC bought a new position in shares of Zoetis in the 3rd quarter valued at $42,000. Institutional investors own 92.80% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Quarterly beat — Zoetis reported adjusted Q4 EPS of $1.48 vs. $1.40 consensus and revenue of about $2.39B, topping estimates; the results show solid margins and modest year-over-year revenue growth. MarketBeat Q4 results
• Positive Sentiment: Raised/strong FY2026 outlook — Management set adjusted EPS guidance of $7.00–$7.10 (above consensus ~6.81) and revenue guidance around $9.8B–$10.0B, pointing to continued strength in companion-animal and international markets. This underpins a constructive longer-term earnings trajectory. Reuters: Zoetis forecasts 2026
• Neutral Sentiment: Investor materials and transcripts available — Full earnings call transcript and slide deck provide more color on regional trends, product mix, and margin assumptions for 2026; these materials will guide how durable the beat and guidance are perceived. Yahoo Finance transcript
• Negative Sentiment: Analyst skepticism on growth trajectory — Several analysts flagged slowing trends in key segments and questioned the sustainability of growth, pressuring sentiment despite the beat and guidance. Benzinga: Analysts question growth
• Negative Sentiment: Outlook nuance and U.S. softness — Coverage notes and commentary highlight that topline growth faces headwinds in the U.S.; investors appear focused on near-term revenue momentum rather than headline EPS/guidance beats. Seeking Alpha: Outlook shows pressure

Zoetis Price Performance

Shares of ZTS opened at $125.58 on Friday. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The company has a market capitalization of $55.34 billion, a price-to-earnings ratio of 21.14, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. The business has a 50-day moving average of $124.26 and a 200-day moving average of $135.72.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the business posted $1.40 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ZTS. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. JPMorgan Chase & Co. cut their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. Finally, BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.